Celcuity (CELC) announced overall survival, OS, data from two patient cohorts evaluated in a Phase 1b trial with gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in combination with palbociclib and either letrozole or fulvestrant, in patients with HR+, HER2-advanced or metastatic breast cancer. Results will be presented in a poster session at the San Antonio Breast Cancer Symposium, SABCS, being held December 10-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The poster presents overall survival data among patients with HR+, HER2- advanced breast cancer who were either treatment-naive or whose disease progressed during prior treatment with a CDK4/6 inhibitor. For the treatment-naive patient cohort, median OS was 77.3 months. For the patients previously treated with a CDK4/6 inhibitor and who received the Phase 3 dose of gedatolisib, median OS was 33.9 months.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CELC:
- Celcuity Inc. Reports Q3 Progress and Financials
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Celcuity reports Q3 EPS (70c), consensus (70c)
- CELC Upcoming Earnings Report: What to Expect?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
